Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use by fragile population, like children, cancer patients and the elderly.
Our first drug, Coacillium, is currently in Phase II/III for the treatment of Alopecia Areata, a debilitating skin condition with intense psychological impact on sufferers, especially in children, and their families.
Coacillium safety profile is unparalleled, hence the authorization granted by health authorities to initiate its development first in children, starting age of 2, before adults.
We expect Coacillium to be approved by 2023, as the first drug for Pediatric Alopecia Areata.
Route de la Corniche 3